|
Divergent behavior of cyclin E and its low molecular weight isoforms to progesterone-induced growth inhibition in MCF-7 cells
Hamed Montazeri1, Saeid Bouzari1, Kayhan Azadmanesh2, Seyed Nasser Ostad3, Mohammad Hossein Ghahremani3
1 Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran
2 Department of Virology, Pasteur Institute of Iran, Tehran, Iran
3 Department of Toxicology-Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| Date of Submission | 22-Jul-2013 |
| Date of Acceptance | 13-Oct-2013 |
| Date of Web Publication | 06-Jan-2015 |
Correspondence Address:
Mohammad Hossein Ghahremani
Department of Toxicology-Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran
Iran
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2277-9175.148299
Background: Progesterone is a steroid hormone that modulates proliferation and differentiation in a cell phase and tissue-specific manner. Its function in breast cancer cells is of great significance since it can predict susceptibility of tumor cells to inhibitory effects of progesterone as adjuvant therapy.
Materials and Methods: Stable clones overexpressing cyclin E (EL) and its low molecular weight isoforms (LMW-Es) were generated and treated with various concentrations of progesterone. Cell proliferation was assessed 24 and 48 h after the treatment. Changes in progesterone receptor (PR) expression were measured by real-time polymerase chain reaction.
Results: Here we demonstrated that overexpression of EL and LMW-Es have divergent effects with regard to progesterone response. We found that progesterone could significantly decrease the growth rate of EL-expressing cells in the second cell cycle after treatment; however, progesterone was ineffective to arrest growth of LMW-Es expressing cells. PR expression level was at control level in EL-expressing cells but was downregulatedin LMW-Esexpressing clones.
Conclusion: These results were in line with progesterone response of studied cells. The drop in PR expression together with altered distribution of p21 and p27 can explain different effects of cyclin E isoforms expression on progesterone responsivity. These data bring cyclin E status of cancer cells as a marker for predicting the efficacy of progesterone treatment. Keywords: Cyclin E, low molecular weight isoforms of cyclin E, progesterone, progesterone receptor
How to cite this article:
Montazeri H, Bouzari S, Azadmanesh K, Ostad SN, Ghahremani MH. Divergent behavior of cyclin E and its low molecular weight isoforms to progesterone-induced growth inhibition in MCF-7 cells. Adv Biomed Res 2015;4:16 |
How to cite this URL:
Montazeri H, Bouzari S, Azadmanesh K, Ostad SN, Ghahremani MH. Divergent behavior of cyclin E and its low molecular weight isoforms to progesterone-induced growth inhibition in MCF-7 cells. Adv Biomed Res [serial online] 2015 [cited 2023 Sep 27];4:16. Available from: https://www.advbiores.net/text.asp?2015/4/1/16/148299 |
| Introduction | |  |
The steroid hormone progesterone is one of the principal regulators of human female reproductive organs, which also plays roles in non-reproductive tissues such as cardiovascular and central nervous system, underlining the omnipresent role of this hormone in physiology. [1],[2] Progesterone mediates its effects through the progesterone receptor (PR), which is expressed at two isoforms PR-A and PR-B. These isoforms have identical ligand-binding (LBD) and DNA-binding domains (DBD) but the processing of the amino-terminal domain (NTD) in PR-A is different. [3],[4] Contrary to proliferative effects of estrogen, progesterone can be either proliferative or differentiative in a tissue-specific manner. [5] As an example, progesterone collaborates with estrogen in proliferation of uterus stromal but inhibits estrogen-induced cell mitosis in the epithelium. [6] Use of progesterone in breast cancer is controversial since it does not exert the inhibitory as it shows in endometrial cancer; however, synthetic progestins have indomitable role in breast cancer treatment. [7],[8] The course of action for the antitumor activity of progestins is yet to be identified but restraint of cell cycle within G 1 phase indicates that these compounds act by affecting expression of the genes involved in progression of cell cycle through G 1 . [9] Investigations for identification of these target genes have mentioned the roles of cyclin-dependent kinases (CDKs) and cyclins including cyclin E. [10],[11],[12],[13],[14]
The role of cyclin E has been extensively studied in breast cancer. [15],[16],[17] The function of this molecule is to promote cell cycle from G 1 to S phase by coupling to its correspondent CDK, CDK2, and phosphorylating its target substrates. [18] Different mechanisms are known to be involved in cyclin E deregulation, such as gene amplification, [19] downregulation of hCDC4, [20] overexpression of miR-27a [21] and most importantly elastase-mediated cleavage of full length protein into low molecular weight isoforms (LMW-Es). [22],[23] LMW-Es have higher affinity to CDK2 but are resistant to be inhibited by cyclin-dependent kinase inhibitors (CKIs), p21 cip1 and p27 kip1 . [24],[25] These hyperactive isoforms also exhibit higher kinase activity, comparing to full length protein, and thereby facilitating transition from G 1 to S phase. [23] Ultimately, LMW-Es generation results in genomic instability, tumorigenesis, and anti-hormonal therapy resistance. [24],[25],[26]
Emerging data suggest extensive crosstalk between progesterone signaling pathways and cell cycle regulators. Among them regulation of PR expression by cyclin D1 [27] ; Inhibition of cyclin D1, cyclin D3, and cyclin E [28] ; and induction of CKIs, p21, p27, and p18 INK4c by progesterone [29],[30] can be mentioned. However, progesterone inhibitory effect in the presence of LMW-Es overexpression has not been studied yet. Because LMW-Es are refractory to inhibitory effects of CKIs, [24] we applied full length cyclin E and LMW-Es overexpressing models to interrogate whether progesterone response is different in these models.
| Materials and methods | | |
0Cell culture and progesterone treatment
MCF-7 human breast cancer cell line purchased from German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany). Cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2mM L-glutamine, 100 units/mL penicillin and 100 μg/mL streptomycin (all from PAA, Austria) at 37°C with 5% CO 2 . Generation of cell lines stably express cyclin E isoforms are described elsewhere. [31] For each isoform of cyclin E, two high expressing clones (HE 1 and HE 2) were selected and propagated for further investigations.
Three days before progesterone treatment, cells were switched to phenol red free RPMI 1640 medium containing 10% charcoal-treated fetal bovine serum (FBS). The day before treatment, cells were seeded in 96-well cell culture plates and on the day of the treatment the above medium was replaced witha medium containing 0.1and 1μM of water-soluble progesterone (Sigma, Germany). Proliferation of stable clones was measured 24 and 48 h after treatment by XTT cell viability dye (Roche, Germany) according to manufacturer's protocol. In each time point, the absorbance was measured at 500nm by Biotek micro plate reader.
RNA extraction and transcript analysis
RNA extraction carried out using Tripure reagent (Roche, Germany) according to the manufacturer's specifications. The quality of RNA was checked by measuring A260/A280 absorbance ratio and by electrophoresis on 1% denaturing agarose gel. cDNA was prepared by reverse transcription of 1 μg of total RNA using 100 ng of random primer and 100 units of MuLV reverse transcriptase (Fermentas, Lithuania) under the conditions recommended by the supplier. Quantitative SYBR green polymerase chain reaction (PCR) reactions were performed in a total volume of 20 μL using Precision-R Master Mix (Primerdesign, UK) by StepOnePlus Real-Time PCR system (Applied Biosystems, Foster City, California, USA). All the reactions were performed in triplicate, and template volume was no more than one tenth of the totalreaction. Quantitative values defined as C t numbers and fold changes in gene expression were calculated by using the formula 2 -ΔΔCt and analyzed by REST software. [32] Results presented as N-fold change (decrease or increase) of target gene. Hypoxanthine phosphoribosyltransferase (HPRT) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used as housekeeping genes. The primer sequences are as followings; for progesterone receptor: Forward 5'-GCAATGGAAGGGCAGCACAACT-3', reverse 5'-GCATCCAGTGCTCTCACAACTCTGAC-3'; for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), forward 5- ACACCCACTCCTCCACCTTG-3' and reverse 5'-TCCAC C ACCCTGTTGCTGTAG-3'; for hypoxanthine phosphoribosyltransferase (HPRT), forward 5- CTG G CGTCGTGATTAGTGATGATGA-3' and reverse 5'-TCGAGCAAGACGTTCAGTCCTGTC-3'.
| Results | | |
0Overexpression of full length cyclin E diminishes cell proliferation in the presence of progesterone
Because cyclin E-CDK2 complex are one of the targets of progesterone in growth arrest process, [28] we used stable clone overexpressing cyclin E isoforms to address the effect of cyclin E on the responsivity to progesterone. The stable clones expressing full length cyclin E (EL), Trunc1 (T1 encoding 44 and 45 kDa), middle Trunc (T mid encoding 40 kDa), and Trunc2 (T2 encoding 33 and 34 kDa) were used. For each isoforms, to limit clonal variations, we have used two high expresser clones (HE 1 and 2) for experiments. Our results revealed that progesterone treatment (at both 0.1 and 1 μM concentrations) had no significant effecton proliferation over a 24-h period for any of the clones (data not shown). However, at a concentration of 1 μM progesterone effectively inhibited proliferation in EL expressing clones. On the other hand, progesterone had no significant growth decrease in LMW-Es expressing cells [Figure 1]. In all the treatments, MCF-7 cell stably transfected with empty pcDNA 3.1 (MCF-7 3.1) was used as control cell line. | Figure 1: EL expressing cells respond distinctly to progesterone treatment. Cells were treated with 0.1 and 1 μM of progesterone and cell proliferation was determined by XTT assay at 48h after treatment (Mean ± SD, n = 3; Two-way ANOVA, Bonferroni post-test, **P < 0.01 compared with MCF-7 3.1)
Click here to view |
Overexpression of LMW-Es but not full length cyclin E downregulates progesterone receptor levels
To gain a better understanding of cellular events leading to susceptibility of EL expressing cells to progesterone, we examined if expression of PR is affected by overexpression of cyclin E isoforms. The PR expression levels in stable transfectants were determined using real-time PCR and the results showed that only in LMW-Es overexpressing cells PR expression is downregulated [Table 1].
| Discussion | | |
In this study we investigatedthe effect of truncated isoforms of cylin E on the proliferation of MCF-7 cells affected by progesterone as a step toward unraveling the effects of progesterone on normal physiology as well as breast cancer. We showed that progesterone cannot inhibit cell proliferation of our target cells within 24 h after treatment, but obviously slowed down the growth rate of only EL expressing cells from the 48 h after treatment. Our results indicate that progesterone had no effect on the proliferation of MCF-7 cells. However, when cyclin E was overexpressed (EL clones), the proliferation was inhibited by progesterone. The clones expressing LMW-Es showed no significant changes in proliferation following progesterone treatments. As shown before progesterone markedly decreases cyclin E-CDK2 activity. [28] Based on these findings we expected to find our stable cell lines more responsive to progesterone inhibitory effect; however, this behavior was not seen in LMW-Es overexpressing cell lines.This phenomenon can be attributed in part by hyperactive nature of LMW-Es. Comparing to EL, these forms bind more effectively to CDK2 and are resistant to be inhibited by p21 and p27 despite efficient binding to these molecules. [24] However, p21 and p27 both show increased association with cyclin E-CDK2 complex following progesterone treatment. [28] Thus, p21 and p27 will be recruited to the complexes, which are refractory to their inhibition and as a result the cell cycle will be continued.
According to our experiments, there could be another explanation for different responses of EL and LMW-Es expressing cells. We found that PR expression was affected by LMW-Es expression and had been downregulated in LMW-Es overexpressing cell lines. The decrease in the level of PR was not associated with EL overexpression, indicating that EL and LMW-Es have different gene regulatory effects and regulation of PR expression lies downstream of LMW-Es levels. As progesterone mediates its effect through PR, lowerPR expression translates to lower activity of progesterone and consequently less effectiveness in controlling the proliferation of LMW-Es expressing cells.
Our results demonstrate regulatory effect of cyclin E expression on progesterone signaling pathways. These findings help us to have a better understanding of regulation of signaling pathways in which EL or LMW-Es are involved. Furthermore, EL and LMW-Es can be considered as markers of the efficacy of progesterone therapy in breast cancer.
| References | | |
| 1. | Mote PA, Graham JD, Clarke CL. Progesterone receptor isoforms in normal and malignant breast. Ernst Schering Found Symp Proc 2007;77-107.  |
| 2. | Graham JD, Clarke CL. Physiological action of progesterone in target tissues. Endocr Rev. 1997;18:502-19. |
| 3. | Lonard DM, O'Malley B W. Nuclear receptor coregulators: Judges, juries, and executioners of cellular regulation. Mol Cell 2007;27:691-700. |
| 4. | Aupperlee MD, Haslam SZ. Differential hormonal regulation and function of progesterone receptor isoforms in normal adult mouse mammary gland. Endocrinology 2007;148:2290-300. |
| 5. | Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocr Rev 1990;11:266-301. |
| 6. | Musgrove EA, Lee CS, Sutherland RL. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol 1991;11:5032-43. |
| 7. | Rose PG. Endometrial carcinoma. N Engl J Med 1996;335:640-9. |
| 8. | Santen RJ, Manni A, Harvey H, Redmond C. Endocrine treatment of breast cancer in women. Endocr Rev 1990;11:221-65. |
| 9. | Musgrove EA, Sutherland RL. Cell cycle control by steroid hormones. Semin Cancer Biol 1994;5:381-9. |
| 10. | Musgrove EA, Hamilton JA, Lee CS, Sweeney KJ, Watts CK, Sutherland RL. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol 1993;13:3577-87. |
| 11. | Musgrove EA, Lee CS, Cornish AL, Swarbrick A, Sutherland RL. Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21. Mol Endocrinol 1997;11:54-66. |
| 12. | Musgrove EA, Sarcevic B, Sutherland RL. Inducible expression of cyclin D1 in T-47D human breast cancer cells is sufficient for Cdk2 activation and pRB hyperphosphorylation. J Cell Biochem 1996;60:363-78. |
| 13. | Prall OW, Sarcevic B, Musgrove EA, Watts CK, Sutherland RL. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem 1997;272:10882-94. |
| 14. | Watts CK, Brady A, Sarcevic B, deFazio A, Musgrove EA, Sutherland RL. Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol Endocrinol 1995;9:1804-13. |
| 15. | Bortner DM, Rosenberg MP. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol Cell Biol 1997;17:453-9. |
| 16. | Keyomarsi K, Herliczek TW. The role of cyclin E in cell proliferation, development and cancer. Prog Cell Cycle Res 1997;3:171-91. |
| 17. | Keyomarsi K, Conte D Jr., Toyofuku W, Fox MP. Deregulation of cyclin E in breast cancer. Oncogene 1995;11:941-50. |
| 18. | Koff A, Giordano A, Desai D, Yamashita K, Harper JW, Elledge S, et al. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science 1992;257:1689-94. |
| 19. | Schraml P, Bucher C, Bissig H, Nocito A, Haas P, Wilber K, et al. Cyclin E overexpression and amplification in human tumours. J Pathol 2003;200:375-82. |
| 20. | Koepp DM, Schaefer LK, Ye X, Keyomarsi K, Chu C, Harper JW, et al. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 2001;294:173-7. |
| 21. | Lerner M, Lundgren J, Akhoondi S, Jahn A, Ng HF, Akbari Moqadam F, et al. MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression. Cell Cycle 2011;10:2172-83. |
| 22. | Harwell RM, Porter DC, Danes C, Keyomarsi K. Processing of cyclin E differs between normal and tumor breast cells. Cancer Res 2000;60:481-9. |
| 23. | Porter DC, Zhang N, Danes C, McGahren MJ, Harwell RM, Faruki S, et al. Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol Cell Biol 2001;21:6254-69. |
| 24. | Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, et al. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 2004;64:3198-208. |
| 25. | Wingate H, Puskas A, Duong M, Bui T, Richardson D, Liu Y, et al. Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression. Cell Cycle 2009;8:1062-8. |
| 26. | Akli S, Bui T, Wingate H, Biernacka A, Moulder S, Tucker SL, et al. Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors. Clin Cancer Res 2010;16:1179-90. |
| 27. | Yang C, Chen L, Li C, Lynch MC, Brisken C, Schmidt EV. Cyclin D1 enhances the response to estrogen and progesterone by regulating progesterone receptor expression. Mol Cell Biol 2010;30:3111-25. |
| 28. | Musgrove EA, Swarbrick A, Lee CS, Cornish AL, Sutherland RL. Mechanisms of cyclin-dependent kinase inactivation by progestins. Mol Cell Biol 1998;18:1812-25. |
| 29. | Groshong SD, Owen GI, Grimison B, Schauer IE, Todd MC, Langan TA, et al. Biphasic regulation of breast cancer cell growth by progesterone: Role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). Mol Endocrinol 1997;11:1593-607. |
| 30. | Swarbrick A, Lee CS, Sutherland RL, Musgrove EA. Cooperation of p27(Kip1) and p18(INK4c) in progestin-mediated cell cycle arrest in T-47D breast cancer cells. Mol Cell Biol 2000;20:2581-91. |
| 31. | Montazeri H, Bouzari S, Azadmanesh K, Ostad SN, Ghahremani MH. P53 but not cyclin E acts in A negative regulatory loop to controlHER-2 expression in MCF-7 breast carcinoma cell line. Acta Med Iran 2013;51:513-9. |
| 32. | Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002;30:e36. |
[Figure 1]
[Table 1]
| This article has been cited by | | 1 |
Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer |
|
| Kelly K. Hunt,Cansu Karakas,Min Jin Ha,Anna Biernacka,Min Yi,Aysegul A. Sahin,Opoku Adjapong,Gabriel N. Hortobagyi,Melissa L. Bondy,Patricia A. Thompson,Kwok Leung Cheung,Ian O. Ellis,Sarah Bacus,W. Fraser Symmans,Kim-Anh Do,Khandan Keyomarsi | | Clinical Cancer Research. 2017; 23(12): 2991 | | [Pubmed] | [DOI] | | | 2 |
Ligand activated progesterone receptor B drives autophagy-senescence transition through a Beclin-1/Bcl-2 dependent mechanism in human breast cancer cells |
|
| Francesca De Amicis,Carmela Guido,Marta Santoro,Francesca Giordano,Ada Donà,Pietro Rizza,Michele Pellegrino,Ida Perrotta,Daniela Bonofiglio,Diego Sisci,Maria Luisa Panno,Donatella Tramontano,Saveria Aquila,Sebastiano Andò | | Oncotarget. 2016; 7(36): 57955 | | [Pubmed] | [DOI] | | | 3 |
Cytoplasmic Cyclin E and Phospho-Cyclin–Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer |
|
| Cansu Karakas,Anna Biernacka,Tuyen Bui,Aysegul Sahin,Min Yi,Said Akli,Jolie Schafer,Angela Alexander,Opoku Adjapong,Kelly K. Hunt,Khandan Keyomarsi | | The American Journal of Pathology. 2016; | | [Pubmed] | [DOI] | | | 4 |
Targeting the Cell Cycle in Breast Cancer |
|
| Jason P.W. Carey,Khandan Keyomarsi | | Breast Diseases: A Year Book Quarterly. 2016; 27(4): 256 | | [Pubmed] | [DOI] | |
|
 |
|
|
|
Search Pubmed for